2014 Annual Paris Melanoma Conference

Meeting Overview

We are pleased to invite you to the 2014 Annual Paris Melanoma Conference, to be held in Paris on 4-5 July 2014.

This conference will cover the most recent updates on scientific developments and the newest clinical information from the American Society of Clinical Oncology (ASCO) Annual Meeting. This blend of clinical and scientific research with clinical practice will offer the unique opportunity for participants to be updated on all aspects of melanoma research. Oral presentations and poster sessions will highlight important developments in the field, including emerging therapies and implementation of new treatment strategies. We are certain you will gain valuable insight into the current status of preclinical melanoma research and the application of new trial data into clinical practice to ultimately improve patient care.

We look forward to welcoming you to the 2014 Annual Paris Melanoma Conference.


Alexander M.M. Eggermont, MD, PhD

Richard Marais, PhD


Participants interested in presenting data should submit abstracts online during the registration process. Abstract submission cannot be done without registering for meeting attendance.

Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final program book and scheduled for oral or poster presentation, as applicable.

Submission Deadline: 16 May 2014

Acceptance notifications and guidelines for poster presentation will be sent on 28 May 2014
If your abstract is not accepted you will get a 100% refund of the paid registration fee.

Abstract Guidelines

  • Follow instructions provided in complete guidelines (link provided above)
  • Abstracts must be written in English
  • Accepted format: Word document, 9 point Arial font, 500 word count limit
  • List affiliations of author(s) as briefly as possible with city, state (if applicable), and country
  • Place an asterisk (*) before the name of the presenting author
  • Use standard and well-accepted abbreviations
  • When using references, use standard and well-accepted formats
  • Abstract content should be single-spaced, typed in sentence case, and contain:
    • Purpose of the study
    • Summarized description of the project
    • Results and conclusions

Continuing Education

An application has been made to the EACCME® for CME Accreditation of this event.

Target Audience

This educational activity is specifically designed for medical and surgical oncologists, dermatologists, research scientists, and other healthcare professionals interested in the treatment of patients with melanoma.

Learning Objectives

Upon completion of this educational activity, attendees should be able to:

  • Discuss recent progress in the understanding of melanoma biology, including advances in epidemiology, diagnosis, classification, and biomarkers
  • Examine current data and new strategies for the prevention of melanoma
  • Describe current standards of care and recent advances in the treatment of patients with melanoma, including emerging strategies for adjuvant and neoadjuvant therapy
  • Examine the evolving role of targeted therapies and immunotherapies in the treatment of melanoma
  • Assess new data from melanoma clinical trials and novel clinical trial designs to address unanswered questions in the field


Alexander M. M. Eggermont, MD, PhD
Cancer Institute Gustave Roussy
Villejuif/Paris-Sud, France

Richard Marais, PhD
CRUK Manchester Institute
Manchester, United Kingdom

Scientific Committee
Reinhard Dümmer, MD
University of Zurich Hospital
Zurich, Switzerland

Alessandro Testori, MD
European Institute of Oncology
Milan, Italy

Caroline Robert, MD, PhD
Cancer Institute Gustave Roussy
Villejuif/Paris-Sud, France

Laurence Zitvogel, MD, PhD
Cancer Institute Gustave Roussy
Villejuif/Paris-Sud, France

Dirk Schadendorf, MD, PhD
University Hospital Essen
Essen, Germany

Roderick Beijersbergen, PhD
Netherlands Cancer Institute
Amsterdam, the Netherlands

Daniel Peeper, PhD
Netherlands Cancer Institute
Amsterdam, the Netherlands

Salem Chouaib, PhD
Cancer Institute Gustave Roussy
Villejuif/Paris-Sud, France

Antoni Ribas, MD, PhD
University of California, Los Angeles
Los Angeles, California, United States

Keith Flaherty, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Alexander Roesch, MD
University Hospital Essen
Essen, Germany

John B. A. G. Haanen, MD, PhD
Netherlands Cancer Institute
Amsterdam, the Netherlands

Yvonne Saenger, MD
The Mount Sinai Hospital
New York, New York, United States

Iris Helfrich, PhD
University Clinic Essen
Essen, Germany

Thomas Tüting, MD
University Hospital Bonn
Bonn, Germany

James Larkin, FRCP, PhD
The Royal Marsden
London, United Kingdom

Stephan Vagner, PhD
Cancer Institute Gustave Roussy
Villejuif/Paris-Sud, France

Georgina Long, MBBS, PhD
University of Sydney
Sydney, Australia

Jeffrey S. Weber, MD, PhD
H. Lee Moffitt Cancer Center
Tampa, Florida, United States


Friday, 4 July
09.00 Opening presentation
Alexander M. M. Eggermont, MD, PhD

Session I: New Drivers and New Targets in Melanoma
Co-Chairs: Dirk Schadendorf, MD, PhD, and Antoni Ribas, MD, PhD
9.15 Oncogene-induced cellular senescence: Mechanisms and drug targets
Daniel Peeper, PhD

9.40 Inflammation-induced phenotypic plasticity and immune escape
Thomas Tüting, MD

10.05 Inter and intrapathway loops in drug resistance: Targeted therapy’s gallow?
Richard Marais, PhD

10.30 Break and poster viewing

Session II: Migration and Metastasis
Co-Chairs: Alessandro Testori, MD, and Reinhard Dümmer, MD
10.55 Investigating drivers for migration in a Caenorhabditis elegans model
Reinhard Dümmer, MD

11.20 Hypoxia in melanoma metastasis and evasion
Salem Chouaib, PhD

11.45 Primary tumors versus metastasis: New experimental models for cancer cell homing
Iris Helfrich, PhD

Luncheon Satellite Symposium (12.30-14.00)

Session III: Advances in Immunotherapy
Co-Chairs: Caroline Robert, MD, PhD, and Jeffrey S. Weber, MD, PhD
14.20 Linking cancer exomes to cancer immunotherapy
John B. A. G. Haanen, MD, PhD

14.45 Impact of targeted therapies on the immune system
Antoni Ribas, MD, PhD

15.10 Combinations of immunotherapies: Ongoing and upcoming trials
Jeffrey S. Weber, MD, PhD

15.35 Brain metastases: Targeted therapy or immunotherapy?
Georgina Long, MBBS, PhD

Session IV: Proffered Papers and Poster Awards (16.00-18.30)
Co-Chairs: Alexander M M Eggermont, MD, PhD, and Antoni Ribas, MD

Saturday, 5 July
Session V: Proffered Papers (08.30-10.00)
Co-Chairs: Alexander M. M. Eggermont, MD, PhD, and James Larkin, FRCP, PhD

Session VI: Advances in Targeted Therapies
Chair: Richard Marais, PhD
10.00 Multidrug-resistant subpopulations in melanoma
Alexander Roesch, MD

10.25 Combinations of targeted therapies: Which intra/interpathway strategies?
Keith Flaherty, MD

10.50 Signaling pathway crosstalk and resistance
Roderick Beijersbergen, PhD

11.15 Newly identified downstream mechanisms of resistance
Stephan Vagner, PhD

Luncheon Satellite Symposium (12.00-13.30)

13.30 Break and poster viewing

Session VII: New Questions and New Clinical Trial Designs
Co-Chairs: Alexander M. M. Eggermont, MD, PhD, and Keith Flaherty, MD
14.00 Talimogene laherparepvec (TVEC): Current results and future directions
Yvonne Saenger, MD

14.25 The Italian electrochemotherapy experience
Alessandro Testori, MD

14.50 Applications of the renal cell cancer experience to melanoma
James Larkin, FRCP, PhD

15.15 Concepts from basic research for the next generation of immunotherapy trials
Laurence Zitvogel, MD, PhD

15.45 The next generation of melanoma clinical trials: Expert perspectives
  • Immunotherapy—Jeffrey S Weber, MD, PhD
  • Targeted therapy—Keith Flaherty, MD
  • Immuno-targeted combinations—Antoni Ribas, MD, PhD
  • Faculty panel discussion

16.45 Closing remarks
Alexander M. M. Eggermont, MD, PhD



Physician/Scientist early registration: €399,00
Physician/Scientist regular registration: €459,00
Physician/Scientist full registration: €599,00

Industry early registration: €399,00
Industry regular registration: €459,00
Industry full registration: €599,00

Nurses / Fellows registration: €219,00*
Pharmacists: €329,00*
EORTC Physician Discount: €100,00*

Registration fees include VAT.

*Supporting documentation of eligibility may be required.

Registration Includes
Access to all sessions and exhibition
Lunch and coffee breaks
Congress documentation

Registration Deadlines
Early registration rate deadline: 16 May 2014
Regular registration rate deadline: 13 June 2014

To Register
You may register online before 13 June 2014 at www.prIMEoncology.org/ParisMelanoma2014. Registration confirmations will be issued upon successful registration, and reminders will be issued before the meeting. To preregister, registration information and payment must be received no later than 13 June 2014 (regular registration rate).

Group Registrations
Group registration will be accepted. Further information will be available upon inquiry at ParisMelanoma2014@prIMEoncology.org.

To receive a refund of registration fees, written notice of cancellation must be received at ParisMelanoma2014@prIMEoncology.org.

The following deadlines and cancellation fees will apply:

Before 16 April 2014, a €75 administrative charge
Before 16 May 2014: a 80% cancellation fee applies on registration fee(s)
From 16 May 2014: a 100% cancellation fee applies on registration fee(s)

Any registration fees remitted will be refunded after the Conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 16 May 2014.

prIME Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.


All inquiries related to the 2014 Annual Paris Melanoma Conference may be addressed to ParisMelanoma2014@prIMEoncology.org


Scheveningseweg 58
2517 KW The Hague
the Netherlands

Tel.: + 31 70 3067190
Fax: + 31 70 3318335
Web: www.prIMEoncology.org


A room block has been reserved at the Novotel Paris Tour Eiffel, Paris (meeting venue), for delegates of the Melanoma Conference.

It is highly recommended that you book your hotel accommodations as early as possible to avoid rooms being sold out. Click Here to Book Now.*

Please use the following code to benefit from the group rate: POMC

Novotel Paris Tour Eiffel
61 Quai de Grenelle
Paris, 75738

Check in time: 15.00 hours
Check out time: 12.00 hours

Single de Luxe room* € 192,50 including breakfast and VAT
Double de Luxe room € 209,55 including breakfast and VAT

* Double room for single occupancy


  • The full stay will be paid at confirmation.
  • The booking can be modified or cancelled until 60 days prior to the event. After this date, the booking will not be refunded or modified.
  • No refunds will be made in case of no-show.

prIME Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

*If clicking does not take you through to the booking page, please copy and paste this link into your browser: http://www.accorhotels.com/lien_externe.svlt?goto=rech_resa&destination=3546&sourceid=POMC&dayIn=30&monthIn=6&yearIn=2014&nightNb=9&preferredCode=POMC&merchantid=par-accorFRxtor=ADC-5009

Untitled Document
  • Support

    Support for this educational activity is provided by:

    Silver Sponsor


    Corporate Sponsor

    amgen oncology

    gsk 3d

    Several options are available to organizations interested in supporting this conference. For more information, please contact Katie Owrey at Katie.Owrey@prIMEoncology.org.


    Most EU citizens only need their national identity card or passport to enter France. Non-EU citizens require a valid passport to enter France, but many countries are exempt from tourist visas. It is essential that you check with the French embassy or consulate in your country before travelling. Without exception, passports must be valid for at least six months after your planned date of departure from France. 

    prIME Oncology will not directly contact embassies and consulates on behalf of applicants. It is the sole responsibility of the delegates to look after their visa requirements.

    Note: Passport and visa requirements are liable to change at short notice.  Travelers are advised to check their entry requirements with their embassy or consulate.


    Click here to print your personalized invitation letter for the Conference. The sole purpose of this letter is to facilitate the delegates' travel visa arrangements, and it does not imply the provision of any financial or other support by the organizers.  All expenses incurred in relation to the Conference are the sole responsibility of the delegate.


    There are 2 metro stations close to the Hotel Novotel Paris Tour Eiffel: Bir Hakeim (line 6) and Charles Michel (line 10). From Bir Hakeim take exit 1 Quai de Grenelle, follow the Quai de Grenelle for about 875 yds (800 m) (the Seine is on your right), the hotel is at no. 61. From the Charles Michel station: take exit 1 Pl. Charles Michel: follow Rue Linois opposite you for 437 yds (400 m), then turn right onto Quai de Grenelle after about 109 yds (100 m).

    Transfer Companies
    For transfers between Orly or Charles de Gaulle airport to Paris you can use one of the transfer companies:
    Parishuttle – book online at Parishuttle or call +33 (0)153 391 818 to reserve your transfer.
    VanOparis – book online at VanOparis or call +33 (0) 665 387 888 to reserve your transfer.


    July in Paris is generally cool to pleasantly balmy. In July, the average temperatures are between 15-24 degrees Celsius (59-66.2 degrees Fahrenheit) with average rainfall at 57 millimeters (2.2 inches).


    Paris is in the Central European time zone (GMT +1)


    French is the official language spoken in Paris, though English is also widely spoken in areas.


    The Euro (EUR) is the official currency in France. Currency can be exchanged at banks, bureaux de change, and some large hotels, though you will get a better exchange rate at the ATMs. Major credit cards are widely accepted, as are travelers’ cheques, particularly in major tourist destinations. Foreign currency is not accepted.


    France's value-added tax (VAT) is known as TVA (taxe sur la valeur ajoutée) and is 20% on most goods except medicine and books, for which it’s 10%. Prices that include TVA are often marked TTC (toutes taxes comprises; literally ‘all taxes included’).


    French law requires that restaurant, café, and hotel bills include a service charge (usually between 12% and 15%). Taxi drivers expect small tips of between 5% and 10% of the fare, though the usual procedure is to round up to the nearest €1 regardless of the fare.


    Security has been heightened, particularly in the transport sector. Unattended luggage left in public places will be removed or destroyed by security staff. While generally safe, visitors to France are advised to take precautions against petty theft and to ensure their personal safety. Thieves and pickpockets operate on the metro and around airports. Bag snatching is also common, particularly on public transport and in shopping centres, and visitors should also be vigilant of luggage while loading bags into and out of hire cars at airports.


    Paris Info


Register Now

Date And Location

Friday, 4 July 2014
09.00 – 18.30

Saturday, 5 July 2014
08.30 – 17.00

Novotel Paris Tour Eiffel
61 Quai de Grenelle
Paris, 75738


This meeting is a prIME Oncology activity.

prIME Oncology

Under the auspices of the EORTC

European Organization for Research and Treatment of Cancer


AIM at Melanoma Foundation

Continuing Education